(Q37396566)

20 August 2017

Secular trends in prostate cancer mortality, incidence and treatment: England and Wales, 1975-2004. (English)

1 reference

20 August 2017

1 reference

Caroline Trotter

10

0 references

Richard M Martin

object named as

Richard M Martin

11

0 references

David E. Neal

object named as

David Neal

6

0 references

David Gunnell

2

object named as

David Gunnell

1 reference

20 August 2017

3

Jenny Donovan

1 reference

20 August 2017

5

Freddie Hamdy

1 reference

20 August 2017

7

Peter Albertsen

1 reference

20 August 2017

8

Julia Verne

1 reference

20 August 2017

Sabina Hussain

1

1 reference

20 August 2017

Sean McPhail

4

1 reference

20 August 2017

Peter Stephens

9

1 reference

20 August 2017

10 January 2008

1 reference

20 August 2017

1 reference

20 August 2017

101

1 reference

20 August 2017

5

1 reference

20 August 2017

547-555

1 reference

A model of the natural history of screen-detected prostate cancer, and the effect of radical treatment on overall survival

20 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2765909

Prostate cancer: screening approaches

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2765909

Radical prostatectomy versus watchful waiting in early prostate cancer

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2765909

20-year outcomes following conservative management of clinically localized prostate cancer

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2765909

Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2765909

Long-term survival rates of patients with prostate cancer in the prostate-specific antigen screening era: population-based estimates for the year 2000 by period analysis

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2765909

Cancer incidence and incidence rates in Japan in 1999: estimates based on data from 11 population-based cancer registries

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2765909

Decreasing mortality rates for prostate cancer: possible role of hormonal therapy?

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2765909

National practice patterns and time trends in androgen ablation for localized prostate cancer

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2765909

Quality improvement report: Improving design and conduct of randomised trials by embedding them in qualitative research: ProtecT (prostate testing for cancer and treatment) study. Commentary: presenting unbiased information to patients can be diffic

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2765909

Natural experiment examining impact of aggressive screening and treatment on prostate cancer mortality in two fixed cohorts from Seattle area and Connecticut

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2765909

Cancer burden in the year 2000. The global picture

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2765909

Death review process in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2765909

International trends and patterns of prostate cancer incidence and mortality

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2765909

Screening for prostate cancer: estimating the magnitude of overdetection

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2765909

Maximum androgen blockade in advanced prostate cancer: a meta-analysis of published randomized controlled trials using nonsteroidal antiandrogens

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2765909

Prostate Cancer Screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: findings from the initial screening round of a randomized trial

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2765909

The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years?

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2765909

Trends in prostate cancer incidence and mortality: an analysis of mortality change by screening intensity.

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2765909

Large-scale randomized prostate cancer screening trials: program performances in the European Randomized Screening for Prostate Cancer trial and the Prostate, Lung, Colorectal and Ovary cancer trial

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2765909

Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the Federal State of Tyrol, Austria

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2765909

Survey of the rate of PSA testing in general practice

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2765909

A controlled trial of leuprolide with and without flutamide in prostatic carcinoma

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2765909

Recent trends in prostate cancer incidence and mortality in southeast England

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2765909

International trends in prostate-cancer mortality in the "PSA ERA".

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2765909

National trends in the epidemiology of prostate cancer, 1973 to 1994: evidence for the effectiveness of prostate-specific antigen screening

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2765909

Report prepared for the Health Technology Assessment panel of the NHS Executive on the diagnosis, management, treatment and costs of prostate cancer in England and Wales

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2765909

Mortality trends by cause of death in England and Wales 1980-94: the impact of introducing automated cause coding and related changes in 1993.

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2765909

Quality-of-life outcomes in men treated for localized prostate cancer.

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2765909

Hormonal treatment at time of radical retropubic prostatectomy for stage D1 prostate cancer: results of long-term followup

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2765909

Patient outcomes and length of hospital stay after radical prostatectomy for prostate cancer: analysis of hospital episodes statistics for England.

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2765909

Insulin-like growth factor-I and growth in height, leg length, and trunk length between ages 5 and 10 years

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2765909

Does current evidence justify prostate cancer screening in Europe?

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2765909

Implementing the UK Medical Research Council (MRC) RT01 trial (ISRCTN 47772397): methods and practicalities of a randomised controlled trial of conformal radiotherapy in men with localised prostate cancer.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2765909

Progress toward identifying aggressive prostate cancer

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2765909

Rates of prostate-specific antigen testing in general practice in England and Wales in asymptomatic and symptomatic patients: a cross-sectional study

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2765909

Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2765909

Recent trends in the use of radical prostatectomy in England: the epidemiology of diffusion.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2765909

Trends in the utilization of androgen-deprivation therapy for patients with prostate carcinoma suggest an effect on mortality

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2765909

Comparison of trends in prostate-cancer mortality in England and Wales and the USA.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2765909

Cancer surveillance series: interpreting trends in prostate cancer--part III: Quantifying the link between population prostate-specific antigen testing and recent declines in prostate cancer mortality

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2765909

Cancer surveillance series: interpreting trends in prostate cancer--part II: Cause of death misclassification and the recent rise and fall in prostate cancer mortality.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2765909

Prostate cancer incidence and mortality in the United States and the United Kingdom

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2765909

Why is the prostate cancer death rate declining in the United States?

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2765909

Screening for prostate cancer

2 September 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.07338.X

Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.07338.X

Increased risk of fatal prostate cancer may explain the rise in mortality in The Netherlands

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.07338.X

Influence of Androgen Suppression Therapy for Prostate Cancer on the Frequency and Timing of Fatal Myocardial Infarctions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.07338.X

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2765909

Effects of Misattribution in Assigning Cause of Death on Prostate Cancer Mortality Rates

3 December 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.07338.X

The effect of the introduction of ICD-10 on cancer mortality trends in England and Wales

21 January 2018

1 reference

12 December 2020

Have transurethral resections contributed to the increasing incidence of prostatic cancer?

1 reference

12 December 2020

An ecologic study of prostate-specific antigen screening and prostate cancer mortality in nine geographic areas of the United States

1 reference

12 December 2020

Phase II Radiation Therapy Oncology Group study of hormonal cytoreduction with flutamide and Zoladex in locally advanced carcinoma of the prostate treated with definitive radiotherapy

1 reference

12 December 2020

Growth and environmental factors in Japan

1 reference

12 December 2020

Overdiagnosis Due to Prostate-Specific Antigen Screening: Lessons From U.S. Prostate Cancer Incidence Trends

1 reference

12 December 2020

Causes of death in elderly prostate cancer patients and in a comparison nonprostate cancer cohort

1 reference

12 December 2020

Rising incidence of prostate cancer in Scotland: increased risk or increased detection?

1 reference

12 December 2020

Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer

1 reference

12 December 2020

Permutation tests for joinpoint regression with applications to cancer rates

1 reference

12 December 2020

Determining cause of death in prostate cancer: are death certificates valid?

1 reference

12 December 2020

Rise in prostatic cancer incidence associated with increased use of transurethral resection

1 reference

12 December 2020

Understanding and appreciating overdiagnosis in the PSA era

1 reference

12 December 2020

Combined androgen blockade in prostate cancer: meta-analyses and associated issues

1 reference

12 December 2020

Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Prostate Cancer Trialists' Collaborative Group

1 reference

12 December 2020

Improved Survival in Patients with Locally Advanced Prostate Cancer Treated with Radiotherapy and Goserelin

1 reference

12 December 2020

10.1111/J.1464-410X.2007.07338.X

Identifiers

DOI

1 reference

20 August 2017

1 reference

20 August 2017

PubMed publication ID

18190630

1 reference